Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Rare SARS-CoV-2 antibody development in cancer patients

 
: Hempel, Louisa; Molnar, Jakob; Robert, Sebastian; Veloso, Julia; Trepotec, Zeljka; Englisch, Sofie; Weinzierl, Philip; Schick, Cordula; Milani, Valeria; Schweneker, Katrin; Fleischmann, Bastian; Scheiber, Josef; Gandorfer, Beate; Kleespies, Axel; Hempel, Dirk; Riedmann, Kristina; Piehler, Armin

:
Fulltext ()

Seminars in oncology (2021), Online First, 6 pp.
ISSN: 0093-7754
ISSN: 1532-8708
English
Journal Article, Electronic Publication
Fraunhofer IOSB ()
SARS-CoV2 antibody development; COVID-19; cancer; immunity

Abstract
SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.

: http://publica.fraunhofer.de/documents/N-622012.html